OC METRO CALENDAR

  • August 2014
    SuMoTuWeThFrSa
    272829303112
    3456789
    10111213141516
    17181920212223
    24252627282930
    31123456
Add an event

MEDICAL RESEARCH
Untitled Page Published: May 14, 2009 10:18 AM





Oxygen Biotherapeutics contracts with U.S. Navy, continued ...

The Navy and the Virginia Commonwealth University Reanimation Shock Center, Oxygen's primary research partner, have a $3.8 million budget for the study of perfluorocarbon therapeutic oxygen carriers. It's welcome news for the company, which doesn't have the funding itself, says Stern.

There is no proven adjunct therapy – or treatments used in conjunction with the primary one – for decompression sickness and arterial gas embolism, he continues. But if the research is met with success and the Navy gets FDA approval, Oxygen could have the option to license the rights from the findings.

Oxygen Biotherapeutics is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and defense medicine.

<< PREVIOUS PAGE


Related headlines
UC Irvine banks $45 million for infectious disease research
NIH: Masimo's SpCo may gauge asthma severity in kids
May is Huntington's Disease Awareness month
UC Irvine Medical Center lands stroke therapy center designation